Ferring's New Chief Falk Talks
Ferring announced this morning (Oct. 31) that Michel Pettigrew is retiring as president of the executive board and will be succeeded by CSO Per Falk. The two spoke to Scrip recently and outlined the Swiss-based firm's future strategy.
You may also be interested in...
The firms have inked a collaboration which aims to explore individual differences in women’s responses to IVF treatment, improve success rates and reduce side effects such as ovarian hyper-stimulation syndrome.
The Swiss company's CMO Klaus Dugi tells Scrip that getting the rights to a late-stage bladder cancer gene therapy from Finland's FKD highlights the transformation that Ferring is undergoing.
Antibody-based therapies have not really been investigated in the area of reproductive medicine and women’s health but Ferring is investing heavily to explore their potential, head of global pharmaceutical R&D Armin Metzger tells Scrip.